Last updated: 2026-09-09 05:11:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
ProKidney Corp. (PROK) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $1.99, with a market capitalization of $419.94M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1.30 to $3.48. This page covers its latest market performance, valuation, price trends and company information.
$419.94M | |
$2.05 | |
$14.19 | |
$0.46 | |
$2.01 | |
874.91K | |
1.21M | |
-- | |
$3.48 | |
$1.30 | |
-- | |
-- |
ProKidney Corp. (PROK) last closed at $2.01 as of 2026-09-08 23:31:00, unchanged from the previous close of $2.01.
During the latest regular trading session, PROK traded between $0.46 and $14.19, with a volume of 874.91K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, ProKidney Corp. (PROK) moved from $1.82 to $1.99, representing a gain of 9.07% ($0.17).
The stock traded between $1.73 and $2.09 during the period. The latest price is near the upper end of the 7-day range, indicating strong upward.
The average daily volume was 980.24 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 31.4%
PROK is currently trading at $1.99, placing it 31.4% of the way from its 52-week low of $1.30 to its 52-week high of $3.48. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
ProKidney Corp is a clinical-stage biotechnology company pioneering the development of a first-in-class, autologous cell therapy that is intended to preserve kidney function in patients with advance chronic kidney disease (CKD) and diabetes. Its product candidate, REACT (Renal Autologous Cell Therapy), is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 231 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of ProKidney Corp. (PROK) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.